US-based bio-pharmaceutical company HDT Bio Corp on Wednesday announced the start of Phase III trial of its COVID-19 vaccine in India.
The Phase III trial of the vaccine developed by HDT Bio in partnership with Gennova Biopharmaceuticals in India is expected to be an affordable one as compared to the existing vaccines in the west.
"This trial is a major milestone for Gennova and us," HDT Bio CEO Steve Reed said.
An important part of the company's mission is establishing value-sharing partnerships with drug firms in historically underserved countries, he said.
"Our goal is to empower our partners to produce and distribute innovative medicines at affordable prices," Steve Reed said.
HDT Bio's innovative vaccine uses a proprietary Lipid Inorganic Nanoparticle (LION) formulation to deliver immune-stimulating RNA fragments to targeted cells, a media release said.
The company said its vaccine is significantly different from current mRNA vaccines in two ways. First, its RNA payload is designed to amplify itself inside the body. As a result, the vaccine effectively activates the immune system at a much lower dose than current vaccines, enhancing safety and reducing manufacturing costs.
Second, the RNA attaches to the outside of the LION system rather than becoming encapsulated within it, simplifying manufacture and enhancing stability.
In July 2020, HDT Bio and Gennova formed a partnership to co-develop the COVID-19 vaccine. As part of the deal, Gennova received the rights to market the vaccine in India. In return, Gennova agreed to provide doses for use in US clinical development and to improve the scalability of the LION technology, the release said.
Clinical trials of HDT Bio's COVID-19 vaccine are expected to begin this year in the US and Brazil. HDT Bio received an $8.2 million grant from the National Institute of Allergy and Infectious Disease at the National Institutes of Health to accelerate the vaccine's development.
HDT Bio has also raised $6 million in a seed round financing led by Zoic Capital.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Bharat Biotech Adds Top Medical Body ICMR As Co-Owner Of Covid Vaccine Patent Covid Vaccinated Pregnant Women At Lower Risk Of Caesarean Births: Study Fact Check: Can Covaxin Lead To Death After 2 Years Of Vaccination? Parents Gave Names Of Interns, Doctors To CBI In Kolkata Horror: Sources How Extreme Weather Is Leading To Rise In Child Marriages In Pakistan Who Is Jasveen Sangha, "Ketamine Queen" Charged With Matthew Perry's Death Two Sisters Returning From Court Run Over By Car In UP: Cops India Sends 1,400 kg Anti-Cancer Drugs To Syria In Humanitarian Assistance Police Arrest Suspect In Bihar Dalit Girl Kidnapping, Murder Case Track Latest News Live on NDTV.com and get news updates from India and around the world.